News
US FDA accepts for priority review Bristol Myers Squibb’s sBLA for Breyanzi to treat adult patients with relapsed or refractory MZL: Princeton, New Jersey Wednesday, August 6, 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback